Financial Ratios Dr. Lal PathLabs Limited
Stocks
LALPATHLAB
INE600L01024
Healthcare Facilities & Services
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,746.60 INR | +1.25% |
|
+3.91% | +17.81% |
| 06-17 | Dr. Lal PathLabs' Volume Boom Comes at a Cost | |
| 05-04 | Nomura Adjusts Dr. Lal PathLabs' Price Target to INR1,860 From INR1,800, Keeps at Buy | MT |
| Fiscal Period: March | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 14.16 | 8.98 | 12.09 | 13.52 | 13.34 | |||||
Return on Total Capital | 16.23 | 10.15 | 13.76 | 15.55 | 15.32 | |||||
Return On Equity % | 24.85 | 14.9 | 20.21 | 24.06 | 21.47 | |||||
Return on Common Equity | 25.05 | 15.08 | 20.35 | 24.22 | 21.57 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 55.94 | 55.78 | 57.44 | 57.86 | 59.49 | |||||
SG&A Margin | 16.64 | 17.74 | 18.57 | 18.29 | 19.04 | |||||
EBITDA Margin % | 24.86 | 21.88 | 25.48 | 26.73 | 26.8 | |||||
EBITA Margin % | 22.88 | 19.5 | 23.42 | 24.88 | 24.74 | |||||
EBIT Margin % | 21.78 | 16.87 | 21.02 | 22.72 | 22.65 | |||||
Income From Continuing Operations Margin % | 16.78 | 11.95 | 16.27 | 20 | 18.45 | |||||
Net Income Margin % | 16.52 | 11.84 | 16.07 | 19.79 | 18.27 | |||||
Net Avail. For Common Margin % | 16.52 | 11.84 | 16.07 | 19.79 | 18.27 | |||||
Normalized Net Income Margin | 13.87 | 10.3 | 13.67 | 15.17 | 15.02 | |||||
Levered Free Cash Flow Margin | -3.05 | 17 | 18.61 | 18.82 | 14.56 | |||||
Unlevered Free Cash Flow Margin | -2.15 | 18.16 | 19.44 | 19.39 | 15.07 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.04 | 0.85 | 0.92 | 0.95 | 0.94 | |||||
Fixed Assets Turnover | 5.63 | 4.84 | 5.93 | 7.17 | 6.67 | |||||
Receivables Turnover (Average Receivables) | 27.45 | 25.82 | 30.04 | 29.74 | 27.79 | |||||
Inventory Turnover (Average Inventory) | 19.34 | 20.66 | 26.65 | 28.25 | 27.99 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.75 | 2.07 | 2.42 | 3.39 | 3.48 | |||||
Quick Ratio | 1.57 | 1.93 | 2.26 | 3.2 | 3.28 | |||||
Operating Cash Flow to Current Liabilities | 0.89 | 0.97 | 1.15 | 1.41 | 1.41 | |||||
Days Sales Outstanding (Average Receivables) | 13.3 | 14.14 | 12.18 | 12.27 | 13.13 | |||||
Days Outstanding Inventory (Average Inventory) | 18.87 | 17.67 | 13.73 | 12.92 | 13.04 | |||||
Average Days Payable Outstanding | 57.22 | 63.43 | 65.93 | 67.89 | 56.3 | |||||
Cash Conversion Cycle (Average Days) | -25.05 | -31.62 | -40.02 | -42.69 | -30.12 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 34.5 | 24.68 | 13.1 | 7.13 | 7.83 | |||||
Total Debt / Total Capital | 25.65 | 19.8 | 11.58 | 6.66 | 7.26 | |||||
LT Debt/Equity | 19.8 | 12.55 | 5.46 | 4.65 | 5.72 | |||||
Long-Term Debt / Total Capital | 14.72 | 10.07 | 4.83 | 4.34 | 5.31 | |||||
Total Liabilities / Total Assets | 34.41 | 28.76 | 23.23 | 18.78 | 19.22 | |||||
EBIT / Interest Expense | 15.07 | 9.06 | 15.95 | 25.07 | 27.45 | |||||
EBITDA / Interest Expense | 18.41 | 12.87 | 20.6 | 31.1 | 34.23 | |||||
(EBITDA - Capex) / Interest Expense | 15.29 | 11.9 | 18.86 | 29.11 | 26.91 | |||||
Total Debt / EBITDA | 0.96 | 0.87 | 0.41 | 0.23 | 0.25 | |||||
Net Debt / EBITDA | -0.27 | -0.82 | -1.15 | -1.45 | -1.45 | |||||
Total Debt / (EBITDA - Capex) | 1.15 | 0.94 | 0.45 | 0.24 | 0.32 | |||||
Net Debt / (EBITDA - Capex) | -0.32 | -0.88 | -1.26 | -1.55 | -1.84 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 32.01 | -3.38 | 10.4 | 10.54 | 12.25 | |||||
Gross Profit, 1 Yr. Growth % | 33.21 | -3.66 | 13.7 | 11.34 | 13.3 | |||||
EBITDA, 1 Yr. Growth % | 30.08 | -14.96 | 28.56 | 15.98 | 12.55 | |||||
EBITA, 1 Yr. Growth % | 31.8 | -17.63 | 32.57 | 17.45 | 11.61 | |||||
EBIT, 1 Yr. Growth % | 26.38 | -25.19 | 37.63 | 19.47 | 11.88 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 18.15 | -31.18 | 50.28 | 35.87 | 3.56 | |||||
Net Income, 1 Yr. Growth % | 18.25 | -30.74 | 49.78 | 36.17 | 3.62 | |||||
Normalized Net Income, 1 Yr. Growth % | 21.4 | -28.25 | 46.55 | 22.68 | 11.14 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 17.93 | -30.86 | 49.55 | 35.88 | 3.42 | |||||
Accounts Receivable, 1 Yr. Growth % | 28.03 | -17.06 | 9.29 | 13.85 | 25.61 | |||||
Inventory, 1 Yr. Growth % | 23.46 | -35.66 | 10.36 | -3.15 | 21.37 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 37.76 | -6.01 | -14.11 | -2.22 | 44.22 | |||||
Total Assets, 1 Yr. Growth % | 41.65 | 1.65 | 2.95 | 10.62 | 15.8 | |||||
Tangible Book Value, 1 Yr. Growth % | -50.23 | 38.83 | 31.11 | 37.8 | 28.67 | |||||
Common Equity, 1 Yr. Growth % | 21.12 | 10.97 | 10.98 | 17.49 | 15.44 | |||||
Cash From Operations, 1 Yr. Growth % | 12.19 | 2.09 | 17.39 | 6.27 | 11.73 | |||||
Capital Expenditures, 1 Yr. Growth % | 164.61 | -61.2 | 40.13 | -13.43 | 277.07 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -121.55 | -637.82 | 20.91 | 12.22 | -13.19 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -114.68 | -916.05 | 18.18 | 10.67 | -12.74 | |||||
Dividend Per Share, 1 Yr. Growth % | -40 | 0 | 100 | 0 | -41.67 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 25.26 | 12.94 | 3.28 | 10.47 | 11.39 | |||||
Gross Profit, 2 Yr. CAGR % | 24.15 | 13.29 | 4.66 | 12.51 | 13.36 | |||||
EBITDA, 2 Yr. CAGR % | 29.87 | 5.18 | 4.56 | 22.11 | 14.25 | |||||
EBITA, 2 Yr. CAGR % | 32.41 | 4.2 | 4.5 | 24.78 | 14.49 | |||||
EBIT, 2 Yr. CAGR % | 29.56 | -2.77 | 1.47 | 28.23 | 15.61 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 24.06 | -9.83 | 1.7 | 42.89 | 18.62 | |||||
Net Income, 2 Yr. CAGR % | 23.54 | -9.5 | 1.85 | 42.81 | 18.79 | |||||
Normalized Net Income, 2 Yr. CAGR % | 24.49 | -6.67 | 2.54 | 34.09 | 16.77 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 23.24 | -9.7 | 1.68 | 42.55 | 18.55 | |||||
Accounts Receivable, 2 Yr. CAGR % | 28.91 | 3.04 | -4.8 | 11.54 | 19.59 | |||||
Inventory, 2 Yr. CAGR % | -3.96 | -10.87 | -15.74 | 3.38 | 8.42 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 19.28 | 13.79 | -10.15 | -8.36 | 18.75 | |||||
Total Assets, 2 Yr. CAGR % | 30.85 | 19.83 | 2.3 | 6.72 | 13.18 | |||||
Tangible Book Value, 2 Yr. CAGR % | -22.45 | -16.87 | 34.92 | 34.41 | 33.16 | |||||
Common Equity, 2 Yr. CAGR % | 20.84 | 15.69 | 10.97 | 14.19 | 16.46 | |||||
Cash From Operations, 2 Yr. CAGR % | 25.44 | 7.02 | 9.47 | 11.69 | 8.96 | |||||
Capital Expenditures, 2 Yr. CAGR % | 41.31 | 1.33 | -26.26 | 10.14 | 80.67 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -43.73 | 7.66 | 155.01 | 16.26 | -1.3 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -53.86 | 9.44 | 210.55 | 14.15 | -1.73 | |||||
Dividend Per Share, 2 Yr. CAGR % | 0 | -22.54 | 41.42 | 41.42 | 8.01 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 20.15 | 14.88 | 12.09 | 5.65 | 11.06 | |||||
Gross Profit, 3 Yr. CAGR % | 18.17 | 14.09 | 13.42 | 6.84 | 13.47 | |||||
EBITDA, 3 Yr. CAGR % | 21.7 | 12.78 | 12.46 | 8.24 | 18.84 | |||||
EBITA, 3 Yr. CAGR % | 23.09 | 13.03 | 12.91 | 8.65 | 20.23 | |||||
EBIT, 3 Yr. CAGR % | 21.15 | 7.88 | 9.17 | 7.14 | 22.53 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 20.45 | 1.94 | 6.91 | 12.01 | 28.35 | |||||
Net Income, 3 Yr. CAGR % | 20.08 | 1.87 | 7.05 | 12.21 | 28.33 | |||||
Normalized Net Income, 3 Yr. CAGR % | 16.35 | 3.6 | 8.48 | 8.86 | 25.96 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 19.85 | 1.64 | 6.83 | 12 | 28.09 | |||||
Accounts Receivable, 3 Yr. CAGR % | 17.07 | 11.29 | 5.08 | 1.05 | 16.05 | |||||
Inventory, 3 Yr. CAGR % | 22.57 | -15.96 | -4.29 | -11.73 | 9.06 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 38 | 10.17 | 3.6 | -7.58 | 6.6 | |||||
Total Assets, 3 Yr. CAGR % | 29.22 | 20.18 | 13.92 | 5 | 9.66 | |||||
Tangible Book Value, 3 Yr. CAGR % | -15.17 | -5.83 | -3.24 | 35.87 | 32.47 | |||||
Common Equity, 3 Yr. CAGR % | 16.84 | 17.29 | 14.1 | 13.11 | 14.6 | |||||
Cash From Operations, 3 Yr. CAGR % | 26.91 | 17.12 | 10.37 | 8.39 | 11.7 | |||||
Capital Expenditures, 3 Yr. CAGR % | 39.26 | -8.15 | 12.89 | -22.21 | 66 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -33.9 | 19.42 | 11.91 | 93.71 | 5.47 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -41.24 | 20.21 | 12.28 | 119.9 | 4.38 | |||||
Dividend Per Share, 3 Yr. CAGR % | 25.99 | 0 | 6.27 | 25.99 | 32.64 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 18 | 13.8 | 13.1 | 13.09 | 11.81 | |||||
Gross Profit, 5 Yr. CAGR % | 16.54 | 12.37 | 12.57 | 13.46 | 13.4 | |||||
EBITDA, 5 Yr. CAGR % | 17.35 | 11.33 | 14.53 | 16.42 | 13.17 | |||||
EBITA, 5 Yr. CAGR % | 17.78 | 11.18 | 15.29 | 17.59 | 13.54 | |||||
EBIT, 5 Yr. CAGR % | 16.67 | 8.02 | 12.85 | 15.6 | 11.7 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 17.62 | 7.02 | 12.56 | 16.68 | 11.45 | |||||
Net Income, 5 Yr. CAGR % | 17.4 | 6.95 | 12.43 | 16.61 | 11.6 | |||||
Normalized Net Income, 5 Yr. CAGR % | 14.54 | 5.2 | 10.62 | 14.86 | 11.72 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 17.01 | 6.66 | 12.22 | 16.37 | 11.37 | |||||
Accounts Receivable, 5 Yr. CAGR % | 15.36 | 11.47 | 7.78 | 11.39 | 10.66 | |||||
Inventory, 5 Yr. CAGR % | 24.02 | 4.34 | 5.51 | -8.7 | 0.6 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 28.32 | 18.99 | 16.23 | 2.35 | 9.42 | |||||
Total Assets, 5 Yr. CAGR % | 27.81 | 21.11 | 17.63 | 14.6 | 13.62 | |||||
Tangible Book Value, 5 Yr. CAGR % | -0.06 | 0.54 | 2.13 | 8.57 | 9.94 | |||||
Common Equity, 5 Yr. CAGR % | 20.42 | 16.16 | 14.36 | 16.04 | 15.04 | |||||
Cash From Operations, 5 Yr. CAGR % | 21.13 | 18.27 | 19.62 | 14.91 | 9.81 | |||||
Capital Expenditures, 5 Yr. CAGR % | 17.74 | -10.18 | 7.99 | -1.23 | 36.25 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -13.58 | 26.35 | 13.43 | 18.14 | 6.34 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | -19.49 | 27.91 | 14.37 | 17.75 | 6.37 | |||||
Dividend Per Share, 5 Yr. CAGR % | 31.95 | 21.67 | 31.95 | 14.87 | 6.96 |
- Stock Market
- Stocks
- LALPATHLAB Stock
- Financials Dr. Lal PathLabs Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















